Lantheus Holdings (LNTH)

$76.43 -1.56 (-2.00%)
Market Cap 5.24B
Revenue (ttm) 1.54B
Net Income (ttm) 233.56M
EPS (ttm) N/A
PE Ratio 15.83
Forward PE 18.72
Profit Margin 15.15%
Debt to Equity Ratio 0.52
Volume 1,890,400
Avg Vol 968,524
Day's Range N/A - N/A
Shares Out 65.10M
Stochastic %K 10%
Beta -0.11
Analysts Strong Sell
Price Target $90.17

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area wi...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 978 671 8001
Fax: 978 671 8860
Address:
201 Burlington Road, South Building, Bedford, United States
RadioIsotope25
RadioIsotope25 Mar. 21 at 8:30 PM
RAD101 upcoming phase 2b data potentially unlocks $RADX against its peers $TLX $LNTH and potentially re-rates stock. Estimated phase 2b completion March 31st, 2026…
1 · Reply
RunFYLife
RunFYLife Mar. 19 at 4:54 PM
$LNTH good opportunity here
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Mar. 18 at 3:49 PM
$LNTH
0 · Reply
alotobeer
alotobeer Mar. 18 at 1:27 PM
$RCKT welcome all $LNTH investors who were playing the March catalyst. Feel free to make money with us while you wait until June
0 · Reply
mikesterz7
mikesterz7 Mar. 17 at 10:36 PM
$LNTH The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29.
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 17 at 8:49 PM
Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application $LNTH $IJH $VTI https://stocktwits.com/news/equity/markets/lantheus-says-fda-pushed-deadline-for-reviewing-tumor-diagnostic-kit-application/cZ3E0YZRIXu
0 · Reply
DonCorleone77
DonCorleone77 Mar. 17 at 8:18 PM
$LNTH Lantheus announces three-month extension of LNTH-2501 PDUFA date Lantheus announced that the FDA has extended its review of the new drug application for LNTH-2501 by three months to June 29. The extension and revised target Prescription Drug User Free Act, or PDUFA, goal date of June 29 will allow the FDA additional time to review and consider further manufacturing related information submitted by Lantheus. This standard review extension is not related to the efficacy or safety data of LNTH-2501.
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 17 at 4:40 PM
RAD 101 Imaging Agent Achieves Concordance with MRI in Suspected Brain Mets | CancerNetwork $RADX $CATX $AKTS $LNTH https://www.cancernetwork.com/view/rad-101-imaging-agent-achieves-concordance-with-mri-in-suspected-brain-mets
0 · Reply
Stackdoe101
Stackdoe101 Mar. 15 at 2:21 AM
$LNTH 🙃✨️
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 13 at 5:12 PM
$LNTH Share Price: $79.51 Contract Selected: Oct 16, 2026 $80 Calls Buy Zone: $11.13 – $13.76 Target Zone: $17.90 – $21.87 Potential Upside: 52% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on LNTH
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Mar 17, 2026, 4:01 PM EDT - 4 days ago

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Mar 6, 2026, 4:01 PM EST - 15 days ago

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

Mar 2, 2026, 12:19 PM EST - 19 days ago

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

Lantheus Holdings, Inc. (LNTH) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:47 PM EST - 22 days ago

Lantheus Holdings, Inc. (LNTH) Q4 2025 Earnings Call Transcript

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:00 AM EST - 23 days ago

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

Feb 12, 2026, 8:00 AM EST - 5 weeks ago

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

Jan 2, 2026, 8:00 AM EST - 2 months ago

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Lantheus Holdings, Inc. (LNTH)

Dec 7, 2025, 11:21 AM EST - 3 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Lantheus Holdings, Inc. (LNTH)

The Bottom Fishing Club - Lantheus Holdings: Interesting Buy Momentum Supporting Price

Nov 13, 2025, 9:28 AM EST - 4 months ago

The Bottom Fishing Club - Lantheus Holdings: Interesting Buy Momentum Supporting Price

Carillon Eagle Small Cap Growth Fund Q3 2025 Portfolio Update

Nov 13, 2025, 1:50 AM EST - 4 months ago

Carillon Eagle Small Cap Growth Fund Q3 2025 Portfolio Update

BRBR MMSI MNDY PI POWL PRM RMBS

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Nov 7, 2025, 9:48 AM EST - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Lantheus Holdings, Inc. (LNTH) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 5:56 PM EST - 4 months ago

Lantheus Holdings, Inc. (LNTH) Q3 2025 Earnings Call Transcript

Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 7:02 AM EST - 4 months ago

Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update

LNTH INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Nov 4, 2025, 11:59 AM EST - 4 months ago

LNTH INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit – LNTH

Oct 30, 2025, 3:58 PM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit – LNTH

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Oct 28, 2025, 9:44 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) DEADLINE ALERT Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline

Oct 27, 2025, 10:08 AM EDT - 5 months ago

LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) DEADLINE ALERT Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Oct 23, 2025, 1:03 PM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

Oct 23, 2025, 8:30 AM EDT - 5 months ago

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

LANTHEUS DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Lantheus Holdings Investors to Contact the Firm Before the November 10th Deadline

Oct 15, 2025, 4:35 PM EDT - 5 months ago

LANTHEUS DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Lantheus Holdings Investors to Contact the Firm Before the November 10th Deadline

Lantheus Holdings: Not An Easy Buy, But The Company Continues To Create Value

Oct 14, 2025, 6:07 AM EDT - 5 months ago

Lantheus Holdings: Not An Easy Buy, But The Company Continues To Create Value

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit - LNTH

Oct 6, 2025, 8:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit - LNTH

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Lawsuit - LNTH

Sep 25, 2025, 8:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Lawsuit - LNTH

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

Sep 24, 2025, 1:00 AM EDT - 6 months ago

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

Sep 22, 2025, 5:29 AM EDT - 6 months ago

Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

Did you lose money in LNTH? Shareholders Who Incurred Significant Losses in Lantheus Holdings, Inc. Should Contact Robbins LLP for Information

Sep 19, 2025, 6:33 PM EDT - 6 months ago

Did you lose money in LNTH? Shareholders Who Incurred Significant Losses in Lantheus Holdings, Inc. Should Contact Robbins LLP for Information

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lantheus Holdings, Inc. (LNTH)

Sep 10, 2025, 8:00 PM EDT - 6 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lantheus Holdings, Inc. (LNTH)

LNTH LAWSUIT: Lantheus Holdings Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Sep 10, 2025, 10:54 AM EDT - 6 months ago

LNTH LAWSUIT: Lantheus Holdings Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

RadioIsotope25
RadioIsotope25 Mar. 21 at 8:30 PM
RAD101 upcoming phase 2b data potentially unlocks $RADX against its peers $TLX $LNTH and potentially re-rates stock. Estimated phase 2b completion March 31st, 2026…
1 · Reply
RunFYLife
RunFYLife Mar. 19 at 4:54 PM
$LNTH good opportunity here
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Mar. 18 at 3:49 PM
$LNTH
0 · Reply
alotobeer
alotobeer Mar. 18 at 1:27 PM
$RCKT welcome all $LNTH investors who were playing the March catalyst. Feel free to make money with us while you wait until June
0 · Reply
mikesterz7
mikesterz7 Mar. 17 at 10:36 PM
$LNTH The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29.
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 17 at 8:49 PM
Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application $LNTH $IJH $VTI https://stocktwits.com/news/equity/markets/lantheus-says-fda-pushed-deadline-for-reviewing-tumor-diagnostic-kit-application/cZ3E0YZRIXu
0 · Reply
DonCorleone77
DonCorleone77 Mar. 17 at 8:18 PM
$LNTH Lantheus announces three-month extension of LNTH-2501 PDUFA date Lantheus announced that the FDA has extended its review of the new drug application for LNTH-2501 by three months to June 29. The extension and revised target Prescription Drug User Free Act, or PDUFA, goal date of June 29 will allow the FDA additional time to review and consider further manufacturing related information submitted by Lantheus. This standard review extension is not related to the efficacy or safety data of LNTH-2501.
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 17 at 4:40 PM
RAD 101 Imaging Agent Achieves Concordance with MRI in Suspected Brain Mets | CancerNetwork $RADX $CATX $AKTS $LNTH https://www.cancernetwork.com/view/rad-101-imaging-agent-achieves-concordance-with-mri-in-suspected-brain-mets
0 · Reply
Stackdoe101
Stackdoe101 Mar. 15 at 2:21 AM
$LNTH 🙃✨️
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 13 at 5:12 PM
$LNTH Share Price: $79.51 Contract Selected: Oct 16, 2026 $80 Calls Buy Zone: $11.13 – $13.76 Target Zone: $17.90 – $21.87 Potential Upside: 52% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 13 at 1:20 PM
$LLY $NVS $RADX $LNTH $AKTS RADX only value play
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 13 at 3:20 AM
It’s possible RAD101 could be a $1 to $1.5 billion dollar brain imaging tracer. If it becomes the gold standard. Brain tumors in general live off fatty acids. Therefore that’s why it finds them and lights them up. But radiologist could potentially use it before stereotactic radiation because mri’s don’t always pick up very small brain Mets and definitely after stereotactic radiation because standard mri’s don’t work well after necrosis cause by the radiation laser (gamma or cyber knife). What’s interesting phase2a 10/10 and phase 2b 11/12. Also, there’s a major market for this in European and Asia as well. $RADX $LNTH $AKTS $CATX
0 · Reply
HappE
HappE Mar. 12 at 8:58 AM
$LNTH Took out the trash a lil tonight with all meme pumpers. Those folks haven't been in this ticker. She's violent, will eat all your shitty stop losses, and generally only rewards those with a stomach. Aug is big could be 2nd blockbuster. It's the next leg, until then holding my core and swinging as usual. Accretion in 26 was goal of our acquisitions.
0 · Reply
Stackdoe101
Stackdoe101 Mar. 12 at 12:25 AM
$LNTH $RLAY
1 · Reply
RadioIsotope25
RadioIsotope25 Mar. 11 at 10:36 PM
Radiopharm: "Hold" As Theranostics Pipeline Has Several 2026 Milestones (NASDAQ:RADX) | Seeking Alpha $RADX $AKTS $NVS $LNTH https://seekingalpha.com/article/4881314-radiopharm-hold-as-theranostics-pipeline-has-several-2026-milestones
2 · Reply
RadioIsotope25
RadioIsotope25 Mar. 11 at 3:31 PM
Rad101 becomes a $1-3 billion asset per year if it becomes a pan tumor imaging agent $RADX $LNTH
0 · Reply
Alacrity2
Alacrity2 Mar. 10 at 10:35 PM
$CATX WOW …. $LNTH is on fire 🔥 the last couple of days!
1 · Reply
RadioIsotope25
RadioIsotope25 Mar. 10 at 2:45 PM
Radiopharm Theranostics (ASX: RAD) KOL Webinar with Dr Ramji Rajendran - YouTube $RADX $CATX $AKTS $LNTH https://www.youtube.com/watch?v=d1lhPMFcrvY
0 · Reply
Cmhatwell
Cmhatwell Mar. 9 at 8:11 PM
$LNTH lfg
1 · Reply
Jcljack26
Jcljack26 Mar. 9 at 6:30 PM
$LNTH when does $LNTH buy the rest of $CATX in an all cash deal?
4 · Reply
focafoca99
focafoca99 Mar. 8 at 9:41 PM
$LNTH the fda approval should be reflected this Monday in the stock price
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 7 at 2:52 PM
RAD101 isn’t just an imaging agent. Trial ending in March. $RADX $DAWN $LNTH $CATX
0 · Reply